Pharmaceutical major Lupin Limited announced its exceptional performance in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving a score of 91 out of 100. This places Lupin among the top 1% of companies worldwide and designates it as the leading pharmaceutical company globally. Furthermore, Lupin topped all sectors in India, reinforcing its commitment to ESG principles across its value chain, marking its third consecutive year in the Sustainability Yearbook.
Lupin Achieves Top Global ESG Ranking
Global pharmaceutical company Lupin Limited has been recognized among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA) for 2025. The company secured an impressive score of 91 out of 100, establishing it as the foremost pharmaceutical firm globally and the sector leader across India, ahead of both domestic and international competitors.
S&P CSA 2025 Performance Metrics
The S&P Global CSA benchmark evaluates companies based on comprehensive industry-specific economic, environmental, and social criteria. Lupin’s high score ensures its inclusion in the prestigious Sustainability Yearbook 2026 for the third consecutive year. Yearbook membership requires companies to rank in the top 15% of their industry. Out of over 9,200 companies assessed across 59 industries, only 848 earned Yearbook inclusion.
Leadership Statement on Sustainability
Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, emphasized the significance of this achievement. He stated that the recognition reinforces the company’s long-term commitment to embedding ESG principles into its core business strategy. This success strengthens Lupin’s resolve to accelerate its sustainability roadmap and deepen ESG integration across its entire value chain to benefit patients, communities, and stakeholders worldwide.
About Lupin’s Sustainability Focus
This latest recognition highlights Lupin’s sustained focus on responsible business practices, robust governance structures, environmental stewardship, and generating positive social impact throughout its global operations.
Lupin Corporate Profile
Lupin Limited is a major pharmaceutical leader headquartered in Mumbai, India, distributing products in over 100 markets. The company specializes in branded and generic formulations, complex generics, and biotechnology products. Lupin operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce exceeding 24,000 professionals.
Source: BSE
